CCO Oncology Podcast

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Episode Summary

Caitlin Costello, MD, discusses the role and safety of bispecific antibodies approved for the treatment of relapsed/refractory multiple myeloma as well as emerging data and clinical trials with this treatment approach.

Episode Notes

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:

• 3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D
• The role of bispecific antibodies in R/R MM
• Safety considerations for patients while receiving a bispecific antibody
• Emerging data and clinical trials with bispecific antibodies
• Key clinical pearls for optimal use of bispecific antibodies

Presenter:

Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Link to full program: 
https://bit.ly/40bjFCZ